Regeneron Pharmaceuticals Inc

Suletud

SektorTervishoid

654.35 4.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

643.27

Max

654.35

Põhinäitajad

By Trading Economics

Sissetulek

-117M

727M

Müük

-279M

3.6B

P/E

Sektori keskmine

15.455

56.269

Aktsiakasum

9.47

Dividenditootlus

0.58

Kasumimarginaal

20.17

Töötajad

15,343

EBITDA

-234M

967M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+26.39% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.58%

2.29%

Järgmine tulemuste avaldamine

30. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-12B

66B

Eelmine avamishind

649.59

Eelmine sulgemishind

654.35

Uudiste sentiment

By Acuity

47%

53%

150 / 342 Pingereas Healthcare

Regeneron Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuli 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

1. juuli 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

30. juuni 2026, 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

29. juuni 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

26. juuni 2026, 23:36 UTC

Regeneron Pharmaceuticals Inc shares are trading higher in after-market hours, moving within a notable range above their 20-day moving average.

25. juuni 2026, 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

24. juuni 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

23. juuni 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

22. juuni 2026, 19:56 UTC

Social Media
News

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

18. juuni 2026, 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

17. juuni 2026, 19:53 UTC

Macro Event

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

16. juuni 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

15. juuni 2026, 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

13. juuni 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

12. juuni 2026, 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

11. juuni 2026, 23:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, rebounding from earlier fluctuations despite no specific news to explain the movement.

10. juuni 2026, 23:11 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, supported by a rise in the Biotechnology sub-sector. The stock remains near its one-month low.

9. juuni 2026, 19:56 UTC

News

Regeneron Pharmaceuticals shares are higher following WHO's endorsement of its antibody therapy maftivimab for clinical trials against Bundibugyo ebolavirus.

8. juuni 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market dynamics influenced by recent U.S. jobs data.

5. juuni 2026, 20:07 UTC

Event

Regeneron Pharmaceuticals shares are higher as Teva launches AHZANTIVE, a biosimilar to Eylea, enhancing its ophthalmology portfolio and impacting Regeneron's competitive position.

4. juuni 2026, 19:56 UTC

Social Media
Event
News
Correlated Moves

Regeneron Pharmaceuticals is gaining momentum ahead of presentations at major medical conferences in June, showcasing new clinical data on key therapies.

3. juuni 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, following a session peak. No specific news was identified to explain the movement.

2. juuni 2026, 23:21 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, driven by gains in the Biotechnology sub-sector, marking a notable change from recent performance.

1. juuni 2026, 20:03 UTC

News

Regeneron Pharmaceuticals is under pressure following an investigation announcement by Bronstein, Gewirtz & Grossman, LLC, amid concerns over trial results. Shares are trading lower.

29. mai 2026, 20:05 UTC

Social Media
News

Regeneron Pharmaceuticals shares declined following the WHO's recommendation to evaluate maftivimab amid an Ebola outbreak in the Democratic Republic of the Congo and Uganda.

28. mai 2026, 23:02 UTC

News
Social Media

Regeneron Pharmaceuticals shares rise after WHO recommends maftivimab for use against the Bundibugyo ebolavirus outbreak in Africa.

27. mai 2026, 23:21 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from recent declines but remain below the 20-day moving average. No specific news was identified.

26. mai 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, continuing a recent trend of declines amid broader market weakness and no specific news identified.

22. mai 2026, 19:37 UTC

Event
News

Regeneron Pharmaceuticals shares are lower today amid investor caution following an investigation into potential claims related to prior trial results.

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

26.39% tõus

12 kuu keskmine prognoos

Keskmine 826.9 USD  26.39%

Kõrge 995 USD

Madal 641 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

15

Osta

6

Hoia

0

Müü

Sentiment

By Acuity

150 / 342 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat